Titan Pharmaceuticals (TTNP) Competitors $4.22 +0.02 (+0.48%) As of 09:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TTNP vs. LIXT, IXHL, CYCC, CARM, AIMD, LEXX, HOTH, LSB, SYBX, and ATNFShould you be buying Titan Pharmaceuticals stock or one of its competitors? The main competitors of Titan Pharmaceuticals include Lixte Biotechnology (LIXT), Incannex Healthcare (IXHL), Cyclacel Pharmaceuticals (CYCC), Carisma Therapeutics (CARM), Ainos (AIMD), Lexaria Bioscience (LEXX), Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Synlogic (SYBX), and 180 Life Sciences (ATNF). These companies are all part of the "pharmaceutical products" industry. Titan Pharmaceuticals vs. Its Competitors Lixte Biotechnology Incannex Healthcare Cyclacel Pharmaceuticals Carisma Therapeutics Ainos Lexaria Bioscience Hoth Therapeutics LakeShore Biopharma Synlogic 180 Life Sciences Titan Pharmaceuticals (NASDAQ:TTNP) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment. Does the media prefer TTNP or LIXT? In the previous week, Lixte Biotechnology had 2 more articles in the media than Titan Pharmaceuticals. MarketBeat recorded 3 mentions for Lixte Biotechnology and 1 mentions for Titan Pharmaceuticals. Titan Pharmaceuticals' average media sentiment score of 1.00 beat Lixte Biotechnology's score of 0.33 indicating that Titan Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Titan Pharmaceuticals Positive Lixte Biotechnology Neutral Which has more volatility & risk, TTNP or LIXT? Titan Pharmaceuticals has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Which has preferable valuation and earnings, TTNP or LIXT? Lixte Biotechnology has lower revenue, but higher earnings than Titan Pharmaceuticals. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Titan Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTitan Pharmaceuticals$180K31.18-$4.71M-$2.95-1.43Lixte BiotechnologyN/AN/A-$3.59M-$1.29-3.54 Is TTNP or LIXT more profitable? Lixte Biotechnology's return on equity of 0.00% beat Titan Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Titan PharmaceuticalsN/A -108.60% -95.64% Lixte Biotechnology N/A N/A -222.90% Do institutionals and insiders have more ownership in TTNP or LIXT? 31.5% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are owned by institutional investors. 0.7% of Titan Pharmaceuticals shares are owned by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryTitan Pharmaceuticals beats Lixte Biotechnology on 6 of the 11 factors compared between the two stocks. Get Titan Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TTNP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TTNP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TTNP vs. The Competition Export to ExcelMetricTitan PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.58M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E Ratio-1.4220.8975.7726.43Price / Sales31.18458.96547.72119.09Price / CashN/A44.5237.0558.92Price / Book1.589.9311.346.06Net Income-$4.71M-$53.38M$3.29B$266.28M7 Day Performance6.94%0.63%0.18%-0.33%1 Month Performance8.23%6.31%6.30%3.43%1 Year Performance-28.60%11.63%57.50%23.10% Titan Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TTNPTitan Pharmaceuticals0.7988 of 5 stars$4.22+0.5%N/A-28.1%$5.58M$180K-1.4210Positive NewsShort Interest ↓LIXTLixte Biotechnology0.7811 of 5 stars$4.10-8.0%N/A+132.8%$18.92MN/A-3.224Short Interest ↓Gap UpIXHLIncannex Healthcare0.5903 of 5 stars$0.63-3.8%N/A-65.7%$18.69M$10K-0.523Short Interest ↓Gap DownCYCCCyclacel Pharmaceuticals1.3996 of 5 stars$8.08-1.9%N/A-97.1%$18.09M$40K-0.0114Positive NewsShort Interest ↓CARMCarisma Therapeutics2.216 of 5 stars$0.43+101.4%$1.93+344.6%-68.0%$17.89M$19.63M-0.2720Negative NewsShort Interest ↑Gap DownHigh Trading VolumeAIMDAinos0.4321 of 5 stars$3.70-3.1%N/A+19.0%$17.24M$20K-0.7440Short Interest ↑LEXXLexaria Bioscience2.904 of 5 stars$0.88+0.1%$4.00+354.0%-71.9%$17.23M$460K-1.317Negative NewsShort Interest ↑HOTHHoth Therapeutics2.6229 of 5 stars$1.30+11.6%$4.00+208.9%+88.8%$17.17MN/A-1.214Positive NewsGap UpHigh Trading VolumeLSBLakeShore Biopharma1.639 of 5 stars$0.82+2.7%N/A-82.1%$17.07M$85.67M0.00773Positive NewsShort Interest ↓SYBXSynlogicN/A$1.45flatN/A-1.4%$17.02M$10K-18.1980Gap UpATNF180 Life Sciences0.3224 of 5 stars$2.81-2.1%N/A+0.8%$16.97MN/A-0.197Gap Up Related Companies and Tools Related Companies Lixte Biotechnology Alternatives Incannex Healthcare Alternatives Cyclacel Pharmaceuticals Alternatives Carisma Therapeutics Alternatives Ainos Alternatives Lexaria Bioscience Alternatives Hoth Therapeutics Alternatives LakeShore Biopharma Alternatives Synlogic Alternatives 180 Life Sciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TTNP) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Titan Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Titan Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
